Psychedelics
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE“), a leader in developing technology to advance psychedelic-related treatments, is pleased to announce the completion of its initial strategic equity investment of equal to approximately 13% ownership in ATMA Journey Centers Inc. (“ATMA“) in accordance with the terms of the letter of intent (the […]
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update
Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant […]
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive license agreement with The University of Kansas for the development and commercialization for the […]
PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio”), a leader in the field of psychedelic research and drug development, has initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc. (“AMRI”), a leading global provider of advanced contract research, development and manufacturing solutions, with expertise in synthetic biology and fermentation development. […]
Optimi Health and Numinus Wellness to Conduct Psychedelic Lab Research and Development
Optimi Health Corp. (CSE: OPTI) (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus”). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible […]
DELIC Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce the appointment of Kyle Snook, former COO of Actify Neurotherapies, to the Board of Advisors of the Company. Matt Stang commented “On behalf of the team at DELIC, I am very excited to welcome Kyle to […]
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative nature-sourced medicine for mainstream use, has completed the world’s first international legal export of dried psilocybin mushrooms. In December 2020, the Company announced the completion […]
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) (“Novamind”), a leading mental health company specialized in psychedelic medicine, today reported its fiscal second quarter results for the three months ended December 31, 2020 (“Fiscal Q2 2021″). The Company’s fiscal year-end is June 30th. All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise […]
PharmaTher Announces DTC Eligibility of Its Common Shares in the United States
Newscope Capital Corporation (“Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce today that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in […]
Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin
Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials. The Company’s wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has successfully […]
Havn Life Sciences to Host Investor Webcast on March 3, 2021
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, announced today that it will host a webcast investor presentation on Wednesday, March 3, at 2:00 p.m. EST (11:00 a.m. PST). During the webcast, CEO Tim Moore will lead a PowerPoint […]
Field Trip Health Announces Upsize to Previously Announced Bought Deal Public Offering
Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce today that, due to strong demand, it has agreed with a syndicate of underwriters led by Bloom Burton Securities Inc. (collectively, the “Underwriters“), to increase the size of its previously […]
MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company
Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF, DE: MMQ) (“MindMed“), a leading psychedelic medicine biotech company, is pleased to announce that it has closed the previously announced acquisition of HealthMode, a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient […]
PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange
PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (TSXV: PSYB) is pleased to announce that at the opening of the market today, the Company’s subordinate voting shares will commence trading on the TSX Venture Exchange (the “TSXV”) under the ticker symbol “PSYB”. On February 19, 2021, the Company announced the closing of its Qualifying Transaction (as […]
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland“, an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil’s National Health Regulatory Agency, has granted authorization for the […]
Nova Mentis Autism Clinical Study Approved by Institutional Review Board
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)(“NOVA”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has obtained Institutional Review Board (IRB) approval of its protocol […]
Yukoterre Announces Conditional Approval of Reverse Takeover Transaction With Silo Wellness
YUKOTERRE RESOURCES INC. (“Yukoterre”) (CSE:YT), is pleased to announce that further to the press release dated August 25, 2020, it has obtained conditional approval from the Canadian Securities Exchange (the “CSE”) for the listing of the common shares (the “Resulting Issuer Shares”) that will result from the reverse takeover (“RTO”) of Yukoterre by FlyOverture Equity […]
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences
Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (“HaluGen“), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to […]
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced an exclusive partnership with Applied Pharmaceutical Innovation (API) at the University of Alberta, as well as expanded capabilities that enables support of […]
Toronto, Ontario–(Newsfile Corp. – February 25, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has expanded its psychedelic pharmaceutical program with […]
VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the closing of its oversubscribed initial public offering on February 24, 2021 (the “Offering”). Pursuant to the Offering, the Company […]
VANCOUVER,BC, Feb. 25, 2021 /CNW/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has executed a definitive share purchase agreement (the “Agreement“) to acquire all of the issued and outstanding shares in the capital of Complex Biotech Discovery Ventures (“CBDV“), a licensed psilocybin and cannabis […]
NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial
Vancouver, B.C. – February 24, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) (“NeonMind”), announces that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. (“Psygen”) for its planned phase 2 human clinical trial expected to begin in Canada later this year. Psygen is a Calgary-based company specializing in the synthetic […]
There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”
“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]
Silo Pharma: A Capital Efficient Strategy Targeting Psychedelics
Psychedelics have the potential to revolutionize mental health disorders that have been woefully underserved by conventional therapies. According to Data Bridge Market Research, psychedelic drug sales will grow from just over $2 billion in 2019 to over $6.8 billion by 2027, which represents a 16.3% compound annual growth rate. Investors have many different options for […]
Havn Life Announces DTC Eligibility of Its Common Shares in the United States
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. The Company’s common shares […]
Lobe Sciences to Present at Virtual One2One Investor Forum
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) announces that Philip Young, CEO and Director, will be interviewed on Tuesday, February 23rd, 2021 at 1:00 pm EST by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, […]
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”), a leader in developing technology to create psychedelic-related treatments, is pleased to announce the addition of Rob Hill to the Board of Directors. Mr. Hill brings over twenty years of senior leadership experience in capital markets, and specific domain expertise in heavily regulated […]
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset“), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has engaged a leading international contract development and manufacturing organization (“CDMO“) to synthesize a 1.0 kg batch of cGMP (i.e. pharmaceutical grade) psilocybin utilizing Mindset’s […]
Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF
Novamind Inc. (CSE:NM | OTC PINK:NVMDF) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has been selected to be included in the underlying index of the Horizons Psychedelic Stock Index ETF (NEO: PSYK) (the “ETF”). Novamind achieves this milestone less than two months after going public on […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Westleaf is a private vertically integrated cannabis company focused on innovative retail experiences, engaging cannabis brands and premium cannabis production.
MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
